The latest sponsored DDW Sitting Down With podcast features Paul Wylie, Director of Multiplex at Abcam looking at enhancing the role of multiplexing in high-throughput screening.
Among the topics Lu Rahman will be discussing with Wylie will be the key challenges scientists face with biomarker and drug discovery and how high-throughput screening can help alleviate this. High throughput with multiplex is valuable for drug discovery and Wylie will provide insight on this as well offering expert opinion on the future of multiplex immunoassays in drug and biomarker discovery.
Tune in to hear what critical factors Wylie believes researchers should consider when choosing an assay for high-throughput screening, as well as to gain a greater understanding of robustness and assay reproducibility. Wylie both outlines the challenges in this field of drug discovery and suggests ways in which these challenges can be overcome.
